Venture financing activity hit the ground running in 2018 after a bumper haul of mega-raises brought the total deal value for January close to $1bn.
The winter chill has not put a freeze on venture financing activity, with January's total deal value leaping three times higher than levels seen in December and a year ago.
Medtech Insight's VC financing deal tracker recorded 31 transactions in January, and from the 30 deals that disclosed financial details, $962.5m was raised in total, making it the most successful January over the last five years.
These impressive takings – a three-fold jump from the $318.4m raised in December and $343.5m in January 2017 – got a big helping hand from the bumper harvest of big-buck fundraisings, with five deals raising over $50m.
This is the highest number of $50m-plus deals ever recorded byMedtech Insightover the five-year period of 2014-2018 and includes a nine-figure $200m round by SomaLogic. (See Table 1)
Table 1: Top 5 Medtech VC Deals, January 2018
|
Ranking |
Company |
Based in |
Product/ Therapy sector |
Amount raised |
Financing round |
Total investment |
|
1 |
SomaLogic |
CO, US |
IVD |
$200m |
Undisclosed |
Undisclosed |
|
2 |
Millipede |
CA, US |
Cardiology |
$90m |
Undisclosed |
Undisclosed |
|
3 |
Personal Genome Diagnostics |
MD, US |
IVD |
$75m |
Series B |
Undisclosed |
|
4 |
Metavention |
MI, US |
Neuromodulation |
$65m |
Series C |
Undisclosed |
|
5 |
DNAnexus |
CA, US |
Bioinformatics |
$58m |
Undisclosed |
Undisclosed |
Source: Medtech Insight VC deal tracker
Boulder, Colorado-based SomaLogic developed the SOMAscanassay for highly multiplexed protein measurement. It can measure around 5,000 proteins in a small sample of serum, plasma, or cerebrospinal fluid. This biomarker analysis can be applied to clinical diagnostics or drug discovery and development applications. It is currently using its proteomics technology to build a biomarker database; the company has analysed over 150,000 samples across more than 50 diseases and plans to add one million more samples by the end of 2020.
Signalling the continued interest from Chinese investors in foreign health care assets, one of SomaLogic's key investor in the $200m funding round is Nan Fung Life Sciences, which invested in hearing aid-developer Eargoin October last year. The other significant investor in this round was Madryn Asset Management.
Molecular diagnostics look likely to continue to be a hot spot for venture investors, with two other companies in this area – Personal Genome Diagnostics and DNAnexus – making the top five biggest VC deals. But the second biggest deal came from cardiology, which is typically follows IVD as the most popular product/therapy sector for investment.
Millipede's $90m equity investment comes from Boston Scientific, which also signed an option to acquire the California firm. The stake in Millipede gives Boston Scientific an asset in the "next big thing" in structural heart, mitral valve repair, and puts it in the race among the other transcatheter heart therapy giants like Edwards and Medtronic, who are already some distance ahead. (Also see "Boston Scientific Hooks In Millipede, But Still Trailing Behind In Mitral Valve Race" - Medtech Insight, 25 Jan, 2018.)
Looking at the most popular areas for investment in January, aside from the usual suspects IVD and cardiology taking top two spots, neuromodulation came third, with four transactions. Indeed, a neuromodulation company, Metavention, made it to the top 5 biggest deals of the month with a $65m series C. Metavention'sMetabolic Neuromodulation Therapyuses a transcather technology to modulate the sympathetic nervous system to control blood glucose levels in Type 2 diabetes patients.
Investors are increasingly interested in neuromodulation, as adoption of bioelectronic medicine technologies gain wider acceptance and better understanding by the clinical community.
Other potential hot areas of investment to look out for, based on 2017 trends, are therapies for chronic diseases such as respiratory disorders and sleep disorders, as well as technologies for better diabetes management.
The total takings for 2017 surpassed the previous years, and with 2018 having had a flying start, the year's venture financing climate might continue to soar in the months to come.
Medtech Insight: 世界の医療機器・医療技術の最新情報
By Derrick Gingery 15 Jan 2021
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Medtech Insight: 世界の医療機器・医療技術の最新情報
By Marion Webb 15 Jan 2021
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its...
Medtech Insight: 世界の医療機器・医療技術の最新情報
15 Jan 2021
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO...
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。
インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com
＊Omdia（ICT産業の情報）に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
Meddevicetracker(メッドデバイストラッカー)は、医療機器の開発状況について適応疾患や医療機器のタイプから検索できるツールです。1,000社以上の会社による5,000を超える製品群、2,000件以上の医療機器の臨床試験など比類ない規模で医療機器市場を網羅しています。
In Vivo(インビボ)は、医療用医薬品の企業全般、バイオ医薬品企業、医療機器・診断機器メーカーの経営層・トップマネジメントを対象としたニュース配信サービスです。35年以上の経験を有するベテランの専門記者とアナリストが様々な観点から今日の医薬品産業を分析し、経営層のハイレベルかつグローバルな情報ニーズに応えるニュースや読み応えのある記事を提供しています。
Pink Sheet(ピンクシート)では、医療用医薬品の承認審査を担当する世界中の規制当局の動きに関するニュースを配信しています。グローバルに拠点を置く専門記者とアナリストが、医療用医薬品の製造・販売許可を得るための申請から、承認を得るまでの進捗をカバーしています。世界の薬事規制は常に変化しており、医薬品メーカーのコンプライアンスに大きな影響を及ぼします。Pink Sheetのニュースなら各市場の医療政策や薬事規制の動向をカバーしているので、安全な臨床試験の計画と実施なども強力にサポートすることができます。
